NCT04572763 - Copanlisib Plus Venetoclax in R/R DLBCL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 8, 2021

Primary Completion Date

October 1, 2025

Study Completion Date

December 1, 2025

Conditions

Diffuse Large B Cell LymphomaRelapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Copanlisib

Intravenous infusion

DRUG

Venetoclax

Tablet taken orally

Trial Locations (3)

Siteman Cancer Center at Washington University, St Louis

City of Hope Cancer Center, Duarte

Dana-Farber Cancer Institute, Boston